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ABSTRACT
A panel of sera from patients with known case histories representative of acute toxoplasmosis (primarily
lymphadenopathy, n = 106), latent toxoplasmosis (asymptomatic, n = 368) and negative samples
(n = 54) was used to evaluate the capacity of five serological tests to differentiate among patients
with acute or latent toxoplasmosis and non-infected individuals. Positive IgA, IgE and IgM ELISA
results and low IgG avidity and complement fixation test (CFT) titres of ‡256 were considered to be
indicative of acute toxoplasmosis. The most sensitive methods were IgM ELISA (98.1%) and CFT
(97.1%), albeit with low specificity (65.0% and 64.5%, respectively) and positive predictive values
(43.3% and 42.7%, respectively). IgG avidity assay and IgE ELISA had the highest specificity (97.7% and
91.7%, respectively) and the highest positive predictive values (89.4% and 75.6%, respectively). The best
association between serological results and clinical findings was obtained with IgE ELISA (86%, as
expressed via Youden’s index). In a subset of 259 samples categorised by the period between the onset of
clinical symptoms and sampling, >50% of patients had enlarged lymph nodes for <4 months, despite a
broad range of differences. However, IgM remained positive for 12–18 months, IgA for 6–9 months and
IgE for 4–6 months. IgG avidity remained low for a maximum of 4 months, after which avidity
increased despite the persistence of enlarged lymph nodes and a positive IgE assay. Detection of IgE
appears to be a highly specific test for confirming the acute nature of Toxoplasma infections that have
been detected by other sensitive methods.
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INTRODUCTION
Toxoplasmosis in post-natally infected immuno-
competent individuals, caused by the protozoan
Toxoplasma gondii, usually occurs in two phases,
acute and latent. Differentiation of these phases is
both clinically and diagnostically decisive. Recent
infection has an acute character and is often
accompanied by clinical symptoms, most fre-
quently lymphadenopathy, low-grade fever and
malaise. In pregnant women, the infection can be
transmitted to the embryo during the acute phase.
In comparison, the subsequent latent phase runs a
course free of clinical signs, and transmission of
the infection to the embryo does not occur in
pregnant women with latent toxoplasmosis.
Permanent antigen stimulation means that indi-
viduals with latent toxoplasmosis usually have
life-long anti-Toxoplasma antibodies [1–3].
Toxoplasma seroprevalence in the general pop-
ulation of the Czech Republic is c. 30% [4], but in
certain seropositive individuals, primarily preg-
nant women, it is difficult to determine whether
the toxoplasmosis is acute or latent [5]. The most
reliable indicator of acute toxoplasmosis is sero-
conversion from a negative to a positive titre, or a
four-fold rise in titre over a 3-week interval [1];
however, at least a preliminary diagnosis is
Corresponding author and reprint requests: P. Kodym,
National Reference Laboratory for Toxoplasmosis, CEM,
National Institute of Public Health, Sˇroba´rova 48, CZ-100 42
Prague 10, Czech Republic
E-mail: petr.kodym@szu.cz
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
usually required upon first examination, and
monitoring trends of antibody response is, in
many cases, not possible. Anti-Toxoplasma IgM
antibodies are considered to be the main marker
of acute toxoplasmosis [6], but the limitations of
tests for IgM, e.g., the persistence of positive
values [7], lack of specificity associated with
rheumatoid factor or other immunopathological
responses [7–9] and innate anti-Toxoplasma IgM
[10], necessitate the use of additional methods,
such as IgA tests or IgG avidity assays. However,
even these methods are not without specific
problems, and it is still impossible to interpret
results with absolute certainty.
Although considered to be a useful marker of
acute infection, detection of anti-Toxoplasma IgE
has been used only rarely for routine diagnostic
purposes. Since 2001, a commercially available
IgE ELISA has been incorporated into the diag-
nostic scheme at the National Reference Laborat-
ory for Toxoplasmosis (Prague, Czech Republic).
The present study evaluated the capability of this
test to confirm acute toxoplasmosis and compared
its performance with that of other diagnostic
methods.
MATERIALS AND METHODS
Patients and sera
In total, 439 patients (97 males aged 0–85 years, median
19 years, and 342 females aged 1–79 years, median 28 years) of
known clinical status were examined. Anti-Toxoplasma-positive
patients were tested repeatedly, but results obtained before the
introduction of the IgE ELISA were not included. The total
number of serum samples analysed was 545. The reasons
given for submitting sera to the National Reference Laboratory
for Toxoplasmosis were: lymphadenopathy (29.3%); follow-up
after clinical toxoplasmosis (25.5%); screening during preg-
nancy (20.8%); differential diagnosis in patients with other
diagnoses (7.3%); a previous finding of anti-Toxoplasma anti-
bodies (5.6%); screening before planned pregnancy (4.7%);
febrile and sub-febrile states and fatigue (2.6%); abortion
(1.1%); and others (3.1%). In a subset of 259 samples, the time
after onset of clinical symptoms (hypertrophy of lymphatic
nodes), as indicated by the patient at the first examination, was
also available; the longest follow-up period was 14 years. The
samples were tested with all currently used serological tests
and were sorted into one of three groups according to the
clinical status reported by the clinician and the serological
results obtained.
Group A: Sera from patients with acute toxoplasmosis. Samples
included in group A were collected from patients with
symptoms of clinical toxoplasmosis, e.g., lymphadenopathy,
sometimes accompanied by febrile temperatures and fatigue.
Acute toxoplasmosis was also confirmed by serological and
clinical follow-up of patients; most tests yielded results
indicative of acute toxoplasmosis (see ’Serological interpret-
ation criteria’); in general, the time after onset of clinical
symptoms did not exceed 5 months.
Group L: Sera from patients with latent (non-acute) toxoplasmosis.
This group included samples from patients with a known
history of toxoplasmosis, who were asymptomatic at the time
of sampling, or whose records were annotated by the attend-
ing clinician as ’check-up testing’, ’marked improvement’, or
’marked decrease in size of lymph nodes’. Characteristically,
the results of most tests were indicative of latent toxoplasmosis
(see ’Serological interpretation criteria’), and the time after
onset of clinical symptoms was >6 months.
Group N: Sera from Toxoplasma-negative individuals. Samples in
group N were taken from patients who, at the time of serum
collection, were not infected with T. gondii and did not have
anti-Toxoplasma antibodies. Sera that generated equivocal
results were not included in the study.
Serological tests
Toxoplasma antigen. The complement fixation test (CFT), IgG
ELISA, IgG avidity assay and Test-Line ELISA kits used a
commercially available antigen (Sevapharma, Prague, Czech
Republic), produced by the Tween–ether preparation method
[11] from whole tachyzoites of the T. gondii P-Cz strain [12].
Complement fixation test. A commercially available CFT (Seva-
pharma) [13] was performed according to the manufacturer’s
recommendations [14].
Triplet IgG avidity assay. An in-house IgG avidity assay [15]
was based on an anti-Toxoplasma IgG ELISA [16], using
porcine anti-human IgG conjugated with horseradish per-
oxidase (Sevapharma). In brief, the assay was performed
using three dilutions of each sera (1:1, 1:5 and 1:25), which
were pipetted, in parallel, on to two antigen-coated micro-
plates (A and B). Before the conjugate was pipetted, plate A
was treated with 6 M urea for 20 min, while plate B was
not. By measuring the absorbance of each serum on plates A
and B, the avidity index (AI) at the optimal serum dilution
(i.e., when the absorbance on plate B was closest to 1.0) was
calculated using the formula
AI ¼ Absorbance A
Absorbance B
with an AI of £0.3 considered to indicate low avidity, and an
AI of >0.3 considered to indicate high avidity.
IgA, IgE and IgM ELISA. Specific IgA, IgE and IgM antibodies
were measured using commercial ELISA kits (Test-Line
Clinical Diagnostics, Brno, Czech Republic), based on the
principle of ELISA capture [17], used according to the
manufacturer’s instructions. In order to evaluate the test
results, a positivity index (PI) was calculated using the formula
PI ¼ Absorbance of tested sample
Absorbance of cut - off control
with PI >1.1 considered positive, PI 0.9–1.1 equivocal, and
PI <0.9 negative.
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Serological interpretation criteria
Negative CFT results (titres <8) were considered to indicate
anti-Toxoplasma-negative samples. The following results were
regarded as indicative of acute toxoplasmosis: positive IgA,
IgE and IgM (PI >1.1); low IgG avidity (AI £0.3); and CFT
titres ‡256. Other results were considered to be indicative of
latent infection.
Statistical methods
To evaluate the discriminative ability of individual methods,
the classification of samples as acute (group A) or latent (group
L) toxoplasmosis was considered to be the reference standard.
The sensitivity, specificity, positive and negative predictive
values and the accuracy (proportion of correctly classified
samples) of each test [18] were calculated (and expressed as
percentages) by testing sera in groups L and A using each
method. Youden’s index (sum of sensitivity and specificity
minus 100) was used as a measure of the overall diagnostic
effectiveness of each test [19]. Robust locally weighted regres-
sion (lowess) with a bandwidth of 0.3 was used to obtain a
smoothed curve, illustrating in scatterplots the trend in
antibody levels ⁄ IgG avidity in terms of the period elapsed
since seroconversion [20]. Statistical analysis was with the
Stata software package v.7.0 (Stata Corporation, College
Station, TX, USA).
RESULTS
Duration of symptomatic acute toxoplasmosis
The persistence of lymphadenopathy is shown in
Table 1.After 2.5–4 months, the lymphnodeswere
swollen in 90% of cases, whereas lymphadeno-
pathy was recorded in only 30% of examinations
4.5–6 months following the onset of symptoms.
Only in four patients (five examinations) did the
lymphadenopathy persist for a period of
>6 months (at least 8.5 months in a girl aged
2 years; for 21 months in a woman aged 23 years
with recurrent lymphadenitis connected with a
defect in immunity; for 24 months in a girl aged
9 years with recurrent cervical lymphadenitis; and
for 48 months in a boy aged 4 yearswith suspected
reactivation of congenital toxoplasmosis). All
patients showed positive values for anti-Toxoplas-
ma IgA, IgG, IgE and IgM, high IgG avidity and,
with the exception of a decline in the case of one
female patient with recurrent lymphadenitis, a
CFT titre of ‡256. All patients examined >6 months
after the onset of lymphadenopathy were without
clinical symptoms of toxoplasmosis.
Characteristics of serological tests
Results with the panel of sera from patients with
acute toxoplasmosis (group A), patients with
latent toxoplasmosis (group L) and anti-Toxoplas-
ma-negative individuals (group N) are summa-
rised in Table 2. All samples from group N gave
negative results with all tests, with the exception
of two non-specific positive results with the IgM
test, one equivocal result with the IgM test and
one equivocal result with the IgE test.
Sera in group A were positive for IgM, with the
exception of two samples that yielded equivocal
results. Negative and equivocal results occurred
sporadically with tests for IgA and IgE. Two
patients, both of whom were IgE-negative upon
initial testing (month 2), gave positive results
when re-examined after 2 months. Similarly, two
patients with IgA-equivocal results in months 1
and 2 converted to positivity. The CFT titre was
‡256, with the exception of one sample from a
patient examined in month 2.5 (titre 128), and two
samples from the above-mentioned female patient
with recurring lymphadenitis.
Table 3 compares the methods evaluated. The
most sensitive methods for detection of acute
Table 1. Persistence of clinical symptoms and positive serological results following Toxoplasma infection
Duration of
toxoplasmosis
(months)
No. of samples
tested
No. (%) of samples
from patients with
clinical symptoms
Distribution (%) results of serological testsa
IgA IgE IgM IgG avidity CFT
+ + ⁄ – – + + ⁄ – – + + ⁄ – – Low High ‡256 8–128
0–2 41 41 (100) 97.6 2.4 0.0 95.1 2.4 2.4 97.6 2.4 0.0 95.1 4.9 100.0 0.0
2.5–4 30 27 (90.0) 90.0 3.3 6.7 90.0 0.0 10.0 90.0 6.7 3.3 70.0 30.0 93.3 6.7
4.5–6 40 12 (30.0) 70.0 12.5 17.5 55.0 25.0 20.0 85.0 5.0 10.0 12.5 87.5 97.5 2.5
6.5–9 35 1 (2.9) 48.6 14.3 37.1 25.7 22.9 51.4 54.3 28.6 17.1 0.0 100.0 74.3 25.7
9.5–12 31 1 (3.2) 38.7 9.7 51.6 16.1 16.1 67.7 54.8 29.0 16.1 0.0 100.0 54.8 45.2
12.5–18 29 0 (0.0) 17.2 6.9 75.9 6.9 20.7 72.4 41.4 20.7 37.9 0.0 100.0 31.0 69.0
18.5–36 25 2 (8.0) 16.0 4.0 80.0 16.0 4.0 80.0 24.0 16.0 60.0 0.0 100.0 32.0 68.0
36.5+ 28 1 (3.6) 7.1 0.0 92.9 3.6 7.1 89.3 21.4 7.1 71.4 0.0 100.0 17.9 82.1
Total 259 85 (32.8) 52.1 7.0 40.9 42.1 12.7 45.2 62.2 13.9 23.9 25.1 74.9 66.8 33.2
+, positive; + ⁄ –, equivocal; –, negative. CFT, complement fixation test.
aPositive IgA, IgE, IgM, low IgG avidity and CFT titres ‡256 were perceived as indicative of acute toxoplasmosis.
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toxoplasmosis were IgM ELISA and CFT, which
also showed a high predictive value for the
negative test. The lowest sensitivity was observed
with the IgG avidity test, although 27 of 29 group
A samples with high IgG avidity were also IgE-
positive. On the other hand, the IgG avidity and
IgE ELISA tests were highly specific. In terms of
successful diagnosis, the IgE ELISA showed the
highest overall test effectiveness (as expressed by
Youden’s index), and both IgE ELISA and the IgG
avidity assay achieved the highest accuracy.
Duration of results indicating acute
toxoplasmosis
Low IgG avidity prevailed in samples taken up to
4 months after the onset of symptoms, while IgE
ELISA was predominantly positive until month 6,
IgA ELISA until month 8, and IgM ELISA and
CFT (titres ‡256) until month 12. However, results
indicating acute toxoplasmosis dropped below
20% after month 4 when measuring IgG avidity,
after month 9 with IgE ELISA, after month 12
with IgA ELISA, and after 3 years with CFT. In
contrast, 21.4% of samples collected >3 years
after the onset of symptoms remained positive
by IgM ELISA (Table 1; Figs 1 and 2). If quanti-
tative results are followed-up, a slight increase in
the mean values of the positivity index (for IgE
and IgM, but not IgA ELISA), or of CFT titres, was
observed in month 1. The IgG avidity index was
low in 84.5% and 12.5% of samples taken in
months 1–4 and 5–6, respectively. In 92.3% of
cases of low avidity, it was confirmed that
£4 months had elapsed since the onset of clinical
symptoms. The decline in CFT titres was very
gradual during the first 6 months, but then
declined sharply during a 2-year period. Negative
values were not recorded for any of the patients,
even after monitoring for several years (Fig. 2).
DISCUSSION
The concept of acute toxoplasmosis is perceived
at two levels: in a temporal sense as a ’recently
acquired’ infection; and in a clinical sense as
’acquired toxoplasmosis with characteristic symp-
toms’. The present study took into account both
Table 2. Serological results for
patients with acute toxoplasmosis,
latent toxoplasmosis, and for un-
infected individuals
Test Result
Group A: acute
toxoplasmosis
(105 samples)
Group L: latent
toxoplasmosis
(386 samples)
Group N: negative
sera
(54 samples)
No. % No. % No. %
IgA ELISA Negative 1 1.0 293 75.9 54 100
Equivocal 3 2.8 26 6.7 0 0.0
Positive 101 96.2 67 17.4 0 0.0
IgE ELISA Negative 4 3.8 307 79.5 53 98.1
Equivocal 2 1.9 47 12.2 1 1.9
Positive 99 94.3 32 8.3 0 0.0
IgM ELISA Negative 0 0.0 190 49.2 51 94.4
Equivocal 2 1.9 61 15.8 1 1.9
Positive 103 98.1 135 35.0 2 3.7
IgG avidity
assay
Avidity low 76 72.4 9 2.3 – –
Avidity high 29 27.6 377 97.7 – –
CFT Negative 0 0.0 0 0.0 54 100.0
Titres 8–128 3 2.9 249 64.5 0 0.0%
Titres ‡256 102 97.1 137 35.5 0 0.0
CFT, complement fixation test.
Table 3. Comparison of five assays
evaluated for the diagnosis of acute
toxoplasmosis
IgA
(positive)
IgE
(positive)
IgM
(positive)
IgG
avidity
(low)
CFT
(titre ‡256)
Sensitivity (%) 96.2 94.3 98.1 72.4 97.1
Specificity (%) 82.6 91.7 65.0 97.7 64.5
Predictive value of a positive test (%) 60.1 75.6 43.3 89.4 42.7
Predictive value of a negative test (%) 98.8 98.3 99.2 92.9 98.8
Accuracy of the test (%) 85.5 92.3 72.1 92.3 71.5
Youden’s index (%) 78.8 86.0 63.1 70.1 61.6
CFT, complement fixation test.
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definitions. The actual time at which a patient is
infected is generally unknown. Studies of well-
documented cases reveal that symptoms occur
2 weeks following infection by tissue cysts [21], or
after 5–18 days following infection by T. gondii
oocysts [22]. The first antibodies may be detected
at the same time [1,23] or 1 week later [21]. The
present results demonstrate that all the antibodies
monitored are present at high levels in the sera of
patients at 2–4 weeks after the onset of symptoms.
The increase in antibody levels must therefore be
very sudden. It appears that IgA levels peak in the
second week following onset of symptoms, while
maximum IgE and IgM values, as well as CFT
titres, are reached after 2 weeks. However, there
is enormous individual variability in antibody
response kinetics. In the third and fourth months,
IgA and IgE values revert to negative values in
some patients. The increase in IgG avidity is
marked, and most patients have high avidity after
month 4. If ongoing lymphadenopathy is accep-
ted as the decisive criterion, acute toxoplasmosis
would generally not exceed a period of 4–
6 months for the majority of patients. However,
isolated cases in which lymphadenopathy and
’acute’ antibody responses last for >1 year tend to
be associated with a deficient immune response.
Assays for antibody detection tend to give
positive results for a period longer than that of the
actual symptoms. The level of IgE antibodies best
follows the dynamics of clinical toxoplasmosis, in
that levels drop below the cut-off for positivity
within 2–3 months of the disappearance of symp-
toms. The decline in IgA levels takes 1–3 months
longer. On the other hand, positive IgM and ⁄ or
high CFT titres can be recorded for several years
after symptoms have declined. Nevertheless, a
high percentage of positive results after a number
of years may be distorted by the fact that some
patients monitored (for periods of up to 14 years)
may have had a problematic decline in antibody
levels following toxoplasmosis.
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Fig. 1. Quantitative results obtained with four anti-Toxoplasma antibody tests—(a) IgA ELISA; (b) IgE ELISA; (c) IgM
ELISA; and (d) IgG avidity test—performed with 231 samples for which the period between the onset of clinical symptoms
and sampling was up to 36 months. ELISA tests were considered positive if the positivity index was >1.1; avidity was
considered low if the avidity index was £0.3.
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In most published studies, an evaluation of
diagnostic tests is based on a comparison with
reference methods (e.g., the survey of 18 studies
evaluating IgM ELISA, summarised by Liesenfeld
et al. [9]). However, the true motivation for testing
is not to determine whether patients have anti-
Toxoplasma IgM, but whether they are suffering
from acute toxoplasmosis. Moreover, no generally
accepted methods are available as reference
standards for the tests evaluated in the present
study, especially for IgE ELISA. Therefore, a
panel of sera with well-characterised case histor-
ies was used to make comparisons. The negative
sera (group N) were not included in the calcula-
tions, as IgG avidity could not be determined.
Many studies avoid inclusion of debatable sera
taken during the period of transformation from
acute to latent infection. Thus, Roberts et al. [24]
did not include ’convalescence’ sera, while Suzuki
et al. [25] compared results with sera from the
acute (1–3 months) and latent (13–38 months)
stages. However, the greatest problems in
diagnostic practice are posed by sera collected
between months 4 and 12, and if the assays
are compared solely using either problem-free
samples from an unequivocally initial stage of
infection, evident late stage latent toxoplasmosis,
or wholly negative samples, all tests would have
near perfect characteristics.
Test-Line kits are used currently by > 40% of
Czech laboratories diagnosing toxoplasmosis. In
regular external laboratory quality control sur-
veys, they yield qualitative results comparable to
products of other (mostly international) compan-
ies [26]. In the present study, IgM was the most
sensitive assay, at the expense of low specificity
[9] and a low positive predictive value caused by
long-term endurance of IgM. Generally, IgM is
still interpreted as being associated directly with
acute toxoplasmosis, and even low-level IgM may
provoke inappropriate interventions, especially in
the case of pregnant women. The CFT results
(assuming titres of 1:256 and over to be indicative
of acute toxoplasmosis) were surprisingly similar
to the IgM ELISA results. CFT, relying on a
different principle than that of immunoassays, is
unaffected by factors that provoke non-specific
positivity in immunoassays. Furthermore, CFT is
highly suitable for quantification of antibodies
and monitoring antibody dynamics, and has been
an important component of the diagnostic scheme
[4]. The most specific method was the IgG avidity
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Fig. 2. Quantitative results of complement fixation tests (CFTs) for 259 samples with a known period between the onset of
clinical symptoms and sampling.
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assay, which, uniquely, provides relevant data
concerning the duration of infection. For low
avidity, the brief period from onset of infection is
more important than ongoing clinical symptoms;
avidity was low in only 72.4% of cases with
lymphadenopathy. Unfortunately, there are few
data available concerning the period post-infec-
tion, during which the disease can be transmitted
from mother to foetus. IgA ELISA is less sensitive
than IgM ELISA [23,27], but has a higher specif-
icity and positive predictive value, and is a
suitable joint method for detection of IgM [28].
IgE ELISA shows lower sensitivity than IgM
assays [29–31], but the present study shows that,
as with IgA, decreased sensitivity is not necessar-
ily caused by failure to form these antibodies, and
can also be caused by delayed or early cessation
of antibody production, resulting in IgE antibod-
ies being undetected during sample collection. Of
all the antibody classes, IgE has the shortest
duration, with positive results for up to 6 months
following onset of symptoms, but this period can
vary from 3 – 5 months to 11 months [31–34].
Foudrinier et al. [30] described two different
kinetic patterns in asymptomatic seroconverters
(short duration) and in seroconverters with overt
toxoplasmosis, in which high IgE levels persist for
a number of months. According to Gross et al.
[33], IgE antibodies seem to be markers of disease
activity.
The main advantages of the IgE ELISA are its
high specificity and positive predictive va-
lue—the highest of all ELISA tests—with gener-
ally adequate sensitivity. Of the tests evaluated in
the present study, the IgE ELISA yielded the
highest proportion of qualitatively accurate re-
sults (i.e., the sum of false-negative and false-
positive results was the lowest), as expressed by
the highest value in Youden’s coefficient. Fur-
thermore, IgE positivity correlated closest with
the persistence of clinical symptoms of toxoplas-
mosis. Thus, determination of IgE levels appears
to be an excellent supplementary method with
which to compensate for the low specificity and
positive predictive value of other highly sensitive
tests for the diagnosis of acute toxoplasmosis.
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